Nimodipina Altan (Nimodipine)

Nimodipine selectively antagonizes L‑type calcium channels on the smooth muscle of cerebral arteries. This inhibition reduces calcium entry, causing the vessels to relax and dilate, which improves cerebral blood flow and counteracts the vasospastic response that can follow a subarachnoid hemorrhage.

The specific dose and infusion rate of Nimodipina Altan are determined by the treating physician based on the patient’s clinical condition, weight, and renal or hepatic function. Prescribers follow established guidelines for intravenous administration in the context of subarachnoid hemorrhage.

The safety of Nimodipina Altan during pregnancy or lactation has not been established. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Nimodipina Altan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Nimodipine is the most widely studied calcium channel blocker for vasospasm prophylaxis and is preferred because of its selective cerebral vasodilatory effect. Other agents, such as magnesium sulfate or endothelin antagonists, have been investigated but lack the robust evidence base and regulatory approval that nimodipine holds for this indication.

Nimodipina Altan must be stored at 2‑8 °C in a refrigerator. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare personnel in a controlled setting, typically using a calibrated infusion pump to deliver the prescribed rate over the recommended duration. Continuous monitoring of blood pressure and cardiac status is advised during the infusion.

Serious adverse events include severe hypotension, myocardial infarction, hepatic dysfunction, and anaphylactic reactions. Patients should be closely monitored for abrupt drops in blood pressure, chest pain, signs of liver injury (elevated enzymes), or allergic manifestations such as rash, bronchospasm, or shock, and appropriate medical intervention should be initiated promptly.

Nimodipina Altan is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. Caution is also advised for individuals with severe hypotension, uncontrolled heart failure, or those receiving other potent vasodilators where additive effects could be dangerous. The prescriber must evaluate each patient’s medical history before initiating therapy.